Plasmacytoma-like post-transplant lymphoproliferative disorder seen in pediatric combined liver and intestinal transplant recipients

Pediatr Blood Cancer. 2013 Nov;60(11):E137-9. doi: 10.1002/pbc.24632. Epub 2013 Jun 27.

Abstract

Post-transplant lymphoproliferative disease (PTLD) is a lymphoproliferative disorder secondary to chronic immunosuppression and is the most common malignancy in transplanted patients [Kamdar et al. Curr Opin Organ Transplant, 2011; 16:274-280]. Although PTLD usually presents as B or T cell lymphoma, plasmacytomas have been reported, mostly in the adult population. Six cases of pediatric plasmacytoma-like PTLD have been reported, all of which were treated with vincristine, adriamycin, and dexamethasone (VAD), high dose dexamethasone alone, or dexamethasone + thalidomide [Tcheng et al. Pediatric Blood Cancer, 2006; 47:218-223; Perry et al. Blood, 2013; 8:1377-1383]. We present two cases of pediatric plasmacytoma-like PTLD in combined liver and small bowel transplant patients both successfully treated with bortezomib and dexamethasone based on multiple myeloma protocols [Kyle and Rajkumar, Clin Lymphoma Myeloma, 2009; 9:278-288; Adams and Kaufmann, Cancer Invest, 2004; 22:304-311].

Keywords: PTLD; multiple myeloma; plasmacytoma; transplantation.

Publication types

  • Case Reports

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Boronic Acids / therapeutic use
  • Bortezomib
  • Child
  • Dexamethasone / therapeutic use
  • Female
  • Humans
  • Immunocompromised Host
  • Infant
  • Intestine, Small / transplantation*
  • Liver Transplantation / adverse effects*
  • Lymphoproliferative Disorders / drug therapy
  • Lymphoproliferative Disorders / immunology*
  • Lymphoproliferative Disorders / pathology*
  • Pyrazines / therapeutic use

Substances

  • Anti-Inflammatory Agents
  • Antineoplastic Agents
  • Boronic Acids
  • Pyrazines
  • Bortezomib
  • Dexamethasone